131 related articles for article (PubMed ID: 29870766)
41. Changes in mRNA expression precede changes in microRNA expression in lesional psoriatic skin during treatment with adalimumab.
Raaby L; Langkilde A; Kjellerup RB; Vinter H; Khatib SH; Hjuler KF; Johansen C; Iversen L
Br J Dermatol; 2015 Aug; 173(2):436-47. PubMed ID: 25662483
[TBL] [Abstract][Full Text] [Related]
42. Biomedical applications of microemulsion through dermal and transdermal route.
Shukla T; Upmanyu N; Agrawal M; Saraf S; Saraf S; Alexander A
Biomed Pharmacother; 2018 Dec; 108():1477-1494. PubMed ID: 30372850
[TBL] [Abstract][Full Text] [Related]
43. Ferulic acid altered IL-17A/IL-17RA interaction and protected against imiquimod-induced psoriasis-like skin injury in mice.
Lo HY; Li CC; Cheng HM; Liu IC; Ho TY; Hsiang CY
Food Chem Toxicol; 2019 Jul; 129():365-375. PubMed ID: 31054998
[TBL] [Abstract][Full Text] [Related]
44. MiR-548a-3p Promotes Keratinocyte Proliferation Targeting PPP3R1 after Being Induced by IL-22.
Zhao X; Li R; Qiao M; Yan J; Sun Q
Inflammation; 2018 Mar; 41(2):496-504. PubMed ID: 29181737
[TBL] [Abstract][Full Text] [Related]
45. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
46. Topical delivery of Cyclosporine A into the skin using SPACE-peptide.
Chen M; Kumar S; Anselmo AC; Gupta V; Slee DH; Muraski JA; Mitragotri S
J Control Release; 2015 Feb; 199():190-7. PubMed ID: 25481447
[TBL] [Abstract][Full Text] [Related]
47. Comparative anti-psoriatic efficacy studies of clobetasol loaded chitin nanogel and marketed cream.
Panonnummal R; Jayakumar R; Sabitha M
Eur J Pharm Sci; 2017 Jan; 96():193-206. PubMed ID: 27615594
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-20 as a target in psoriasis treatment.
Stenderup K; Rosada C; Worsaae A; Clausen JT; Norman Dam T
Ann N Y Acad Sci; 2007 Sep; 1110():368-81. PubMed ID: 17911452
[TBL] [Abstract][Full Text] [Related]
49. MiR-217 is down-regulated in psoriasis and promotes keratinocyte differentiation via targeting GRHL2.
Zhu H; Hou L; Liu J; Li Z
Biochem Biophys Res Commun; 2016 Feb; 471(1):169-76. PubMed ID: 26826389
[TBL] [Abstract][Full Text] [Related]
50. The contribution of feedback loops between miRNAs, cytokines and growth factors to the pathogenesis of psoriasis.
Masalha M; Sidi Y; Avni D
Exp Dermatol; 2018 Jun; 27(6):603-610. PubMed ID: 29479749
[TBL] [Abstract][Full Text] [Related]
51. Characterization of starch Pickering emulsions for potential applications in topical formulations.
Marku D; Wahlgren M; Rayner M; Sjöö M; Timgren A
Int J Pharm; 2012 May; 428(1-2):1-7. PubMed ID: 22366058
[TBL] [Abstract][Full Text] [Related]
52. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis.
Nemati H; Ghahramani MH; Faridi-Majidi R; Izadi B; Bahrami G; Madani SH; Tavoosidana G
J Control Release; 2017 Dec; 268():259-268. PubMed ID: 29074408
[TBL] [Abstract][Full Text] [Related]
53. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.
Sathe P; Saka R; Kommineni N; Raza K; Khan W
Drug Dev Ind Pharm; 2019 May; 45(5):826-838. PubMed ID: 30764674
[TBL] [Abstract][Full Text] [Related]
54. miR-340 Alleviates Psoriasis in Mice through Direct Targeting of IL-17A.
Bian J; Liu R; Fan T; Liao L; Wang S; Geng W; Wang T; Shi W; Ruan Q
J Immunol; 2018 Sep; 201(5):1412-1420. PubMed ID: 30012847
[TBL] [Abstract][Full Text] [Related]
55. Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis.
Sonawane R; Harde H; Katariya M; Agrawal S; Jain S
Expert Opin Drug Deliv; 2014 Dec; 11(12):1833-47. PubMed ID: 25078031
[TBL] [Abstract][Full Text] [Related]
56. miRNA miR-17-92 cluster is differentially regulated in the imiqumod-treated skin but is not required for imiqumod-induced psoriasis-like dermatitis in mice.
Wu D; Bi X; Qu L; Han L; Yin C; Deng J; Dong Z; Mi QS; Zhou L
Exp Dermatol; 2017 Jan; 26(1):82-84. PubMed ID: 27579777
[TBL] [Abstract][Full Text] [Related]
57. Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy.
Zhang YT; Shen LN; Wu ZH; Zhao JH; Feng NP
Int J Pharm; 2014 Aug; 471(1-2):449-52. PubMed ID: 24907596
[TBL] [Abstract][Full Text] [Related]
58. Development and evaluation of colloidal modified nanolipid carrier: application to topical delivery of tacrolimus, Part II--in vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis.
Pople PV; Singh KK
Eur J Pharm Biopharm; 2013 May; 84(1):72-83. PubMed ID: 23246619
[TBL] [Abstract][Full Text] [Related]
59. Enhancing topical analgesic administration: review and prospect for transdermal and transbuccal drug delivery systems.
Sanz R; Calpena AC; Mallandrich M; Clares B
Curr Pharm Des; 2015; 21(20):2867-82. PubMed ID: 25925112
[TBL] [Abstract][Full Text] [Related]
60. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis.
Meisgen F; Xu N; Wei T; Janson PC; Obad S; Broom O; Nagy N; Kauppinen S; Kemény L; Ståhle M; Pivarcsi A; Sonkoly E
Exp Dermatol; 2012 Apr; 21(4):312-4. PubMed ID: 22417311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
